Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis.

The aim of this work was to evaluate the efficacy and safety of botulinum toxin A (BTX-A) treatment in patients with neurogenic detrusor overactivity. PUBMED, EMBASE, and Cochrane Library were identified on 13 May 2017 to identify relevant randomized controlled trials. All data obtained were analyzed using Stata 12.0. Five randomized controlled trials were included in this study. Compared to placebo, the BTX-A groups had significantly fewer urinary incontinence (UI) episodes per day and per week (BTX-A with 300?U for frequency of UI per day at week 2, mean difference (MD): ?1.13, 95% confidence interval (CI): ?1.89 to ?0.37; 200?U; BTX-A with 300?U for frequency of UI per week at week 6, MD: ?11.42, 95% CI: ?13.91 to ?8.93; BTX-A with 200?U for frequency of UI per week at week 6, MD: ?10.72, 95% CI: ?13.40 to ?8.04), increased in maximum cystometric capacity at week 6 (BTX-A with 300?U, MD: 154.88, 95% CI: 133.92?175.84; BTX-A with 200?U, MD: 141.30, 95% CI: 121.28?161.33), decreased maximum detrusor pressure at week 6 (BTX-A with 300?U, MD: ?31.72, 95% CI: ?37.69 to ?25.75; BTX-A with 200?U, MD: ?33.47, 95% CI: ?39.20 to ?27.73). For adverse effects, BTX-A was often associated with more complications and urinary tract infections (BTX-A with 300?U: relative risk (RR):1.42, 95% CI: 1.15?1.76; BTX-A with 200?U: RR: 1.42, 95% CI: 1.11?1.82). This meta-analysis suggests that treatment with BTX-A is effective and safe for neurogenic detrusor overactivity, and recommends using BTX-A with 300?U or with 200?U, as suitable dosage.